# Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective

> Research article (Annals of Oncology, 2019) · cited 61× · AI/ML

**Wikidata**: [openalex:W2912537198](https://www.wikidata.org/wiki/openalex:W2912537198)  
**Source**: https://4ort.xyz/entity/model-informed-drug-development-approach-supporting-approval-of-the-4-week-q4w-dosing-schedule-for-nivolumab-opdivo-acro